Renal failure · 2025
Effect of finerenone on proteinuria reduction in IgA nephropathy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yu Guizhen, Wang Meifang, Zhang Xue, Tao Juan, Zhao Jie, Liu Shanshan, Zhou Suhan, Zhou Jingyi, Ren Pingping, Cheng Jun, Chen Jianghua
Аннотация
BACKGROUND: Recent studies have suggested a protective effect of finerenone on renal function and reduced the risk of cardiovascular events in patients with CKD and type 2 diabetes. However, its role in IgA nephropathy remains unknown. This study aimed to evaluate its efficacy against IgA nephropathy.
METHODS: A total of 18 IgAN patients with full supportive therapy, including RAS blockade as much as allowed or tolerated, blood pressure control and steroids and/or other immunosuppressive agents. Analyzed at 2, 4, 6 and 8 months after finerenone therapy.
RESULTS: Eighteen IgA nephropathy patients were enrolled in this study, after 6.78 ± 3.47 months follow-up, a significant reduction was observed in protein-to-creatinine ratio with a 28.48% (p = 0.003), 13.12% (p = 0.17), 31.33% (p = 0.003), 39.69% (p = 0.02), respectively, at 2, 4, 6 and 8 months of treatment with finerenone compared to baseline. The eGFR was relatively stable during follow-up.
CONCLUSIONS: The protein-to-creatinine ratio was significantly reduced after finerenone treatment in IgA nephropathy patients with full supportive therapy, and the eGFR was stable during follow-up.
METHODS: A total of 18 IgAN patients with full supportive therapy, including RAS blockade as much as allowed or tolerated, blood pressure control and steroids and/or other immunosuppressive agents. Analyzed at 2, 4, 6 and 8 months after finerenone therapy.
RESULTS: Eighteen IgA nephropathy patients were enrolled in this study, after 6.78 ± 3.47 months follow-up, a significant reduction was observed in protein-to-creatinine ratio with a 28.48% (p = 0.003), 13.12% (p = 0.17), 31.33% (p = 0.003), 39.69% (p = 0.02), respectively, at 2, 4, 6 and 8 months of treatment with finerenone compared to baseline. The eGFR was relatively stable during follow-up.
CONCLUSIONS: The protein-to-creatinine ratio was significantly reduced after finerenone treatment in IgA nephropathy patients with full supportive therapy, and the eGFR was stable during follow-up.